SCHEMBL21054644

SCHEMBL21054644

CNC(=O)c1ccc(Nc2ccc(C(F)(F)F)cc2)c(-c2nnn(C)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 9/20 0.46
▸ MAPK14 Q16539 2/20 0.44
▸ AKR1C3 P42330 1/20 0.44
▸ AKR1C2 P52895 1/20 0.44
▸ TLR2 O60603 1/20 0.43
▸ TLR1 Q15399 1/20 0.43
▸ TEAD1 P28347 1/20 0.41
▸ YAP1 P46937 1/20 0.41
▸ ACSS2 Q9NR19 1/20 0.40
▸ ABCB1 P08183 2/20 0.40
▸ PTK2 Q05397 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ P2RY14 Q15391 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21054627 0.89 AKR1C3 (0.51) ABCG2AKR1C3AKR1C2TEAD1YAP1
SCHEMBL30062663 0.89 AKR1C3 (0.51) ABCG2AKR1C3AKR1C2TEAD1YAP1
SCHEMBL21090678 0.89 ABCG2 (0.46) ABCG2MAPK14AKR1C3AKR1C2ABCB1
SCHEMBL30061311 0.89 ABCG2 (0.46) ABCG2MAPK14AKR1C3AKR1C2ABCB1
SCHEMBL30061347 0.89 ABCG2 (0.44) ABCG2AKR1C3AKR1C2TEAD1YAP1
SCHEMBL21054684 0.89 AKR1C3 (0.47) AKR1C3AKR1C2SCN9A
SCHEMBL21090761 0.89 ABCG2 (0.44) ABCG2AKR1C3AKR1C2TEAD1YAP1
SCHEMBL25791011 0.89 TP53 (0.41) ABCG2MAPK14AKR1C3AKR1C2TLR2
SCHEMBL30062661 0.88 AKR1C3 (0.45) ABCG2AKR1C3AKR1C2TEAD1YAP1
SCHEMBL21054808 0.88 AKR1C3 (0.45) ABCG2AKR1C3AKR1C2TEAD1YAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
US-11524943-B1 Benzocarbonyl compounds VIVACE THERAPEUTICS, INC. (US) 2022-12-13 — — US disclosed
US-11524943-B1 Benzocarbonyl compounds VIVACE THERAPEUTICS, INC. (US) 2022-12-13 — — US disclosed
EP-3720430-A1 BENZOCARBONYL COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-10-14 — — EP disclosed
WO-2019113236-A1 BENZOCARBONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-06-13 — — WO disclosed
WO-2019113236-A1 BENZOCARBONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524943-B1 Benzocarbonyl compounds YAP1, TEAD2, TEAD3 ABCG2 2776/4885MAPK14 1890/4885AKR1C3 4086/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 ABCG2 2217/4885MAPK14 2780/4885AKR1C3 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback